---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002247"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:31:54.447678+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Liquidia closes $75M PIPE, draws $25M debt facility, files counterclaims in UTHR patent suit

## Summary
- Closed private placement of 7.18M shares at $10.442/share for ~$75M gross proceeds; additional $25M drawn under revenue interest financing amendment.
- Filed response to UTHR patent suit seeking dismissal of invalidated '793 patent claims and asserting counterclaims that '327 patent is invalid due to undisclosed prior art.
- Enrolled first PH-ILD patient in YUTREPIA ASCENT study; PDUFA date for tentative approval is Jan 24, 2024.
- FDA agreed that single Phase 3 trial of L606 in PH-ILD will support both PAH and PH-ILD indications; global study to start later in 2024.

## SEC filing metadata
- accession: 0001104659-24-002247
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465924002247/0001104659-24-002247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465924002247/tm242158d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002247
- JSON: https://secwatch.observer/filing/0001104659-24-002247.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.